Capricor Therapeutics (CAPR) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 09, 2021
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Entity File Number	001-34058
Entity Registrant Name	CAPRICOR THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-0363465
Entity Address, Address Line One	8840 Wilshire Blvd., 2nd Floor,
Entity Address, City or Town	Beverly Hills
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90211
City Area Code	310
Local Phone Number	358-3200
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	CAPR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,149,155
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001133869
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 40,839,158	$ 32,665,874
Receivables	180,178	0
Prepaid expenses and other current assets	278,909	1,011,209
TOTAL CURRENT ASSETS	41,298,245	33,677,083
PROPERTY AND EQUIPMENT, net	1,513,575	850,847
OTHER ASSETS
Intangible assets, net of accumulated amortization of $259,682 and $257,517, respectively	0	2,165
Other assets	288,701	88,701
TOTAL ASSETS	43,100,521	34,618,796
CURRENT LIABILITIES
Accounts payable and accrued expenses	2,988,292	2,724,593
Note payable, current	0	246,689
TOTAL CURRENT LIABILITIES	2,988,292	2,971,282
LONG-TERM LIABILITIES
Note payable, net of current	0	71,471
CIRM liability	3,376,259	3,376,259
TOTAL LONG-TERM LIABILITIES	3,376,259	3,447,730
TOTAL LIABILITIES	6,364,551	6,419,012
COMMITMENTS AND CONTINGENCIES (NOTE 7)
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value, 50,000,000 shares authorized, 24,149,155 and 20,577,123 shares issued and outstanding, respectively	24,149	20,577
Additional paid-in capital	138,581,576	116,216,966
Accumulated deficit	(101,869,755)	(88,037,759)
TOTAL STOCKHOLDERS' EQUITY	36,735,970	28,199,784
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 43,100,521	$ 34,618,796

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
CONDENSED CONSOLIDATED BALANCE SHEETS
Net of accumulated amortization (in dollars)	$ 259,682	$ 257,517
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	24,149,155	20,577,123
Common stock, shares outstanding	24,149,155	20,577,123

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
REVENUE
Revenue		$ 16,863	$ 244,898	$ 252,420
TOTAL REVENUE		16,863	244,898	252,420
OPERATING EXPENSES
Research and development	$ 2,513,915	2,629,267	9,307,512	5,711,896
General and administrative	1,800,630	1,301,673	5,496,186	4,049,955
TOTAL OPERATING EXPENSES	4,314,545	3,930,940	14,803,698	9,761,851
LOSS FROM OPERATIONS	(4,314,545)	(3,914,077)	(14,558,800)	(9,509,431)
OTHER INCOME (EXPENSE)
Other income	367,168		367,168
Investment income	15,570	3,953	41,476	30,335
Forgiveness of debt			318,160	0
TOTAL OTHER INCOME (EXPENSE)	382,738	3,953	726,804	30,335
NET LOSS	(3,931,807)	(3,910,124)	(13,831,996)	(9,479,096)
OTHER COMPREHENSIVE INCOME (LOSS)
Net unrealized gain on marketable securities	0	0	0	757
COMPREHENSIVE LOSS	$ (3,931,807)	$ (3,910,124)	$ (13,831,996)	$ (9,478,339)
Net loss per share, basic	$ (0.17)	$ (0.20)	$ (0.61)	$ (0.68)
Weighted average number of shares, basic	23,095,375	19,801,841	22,731,638	13,958,507
Net loss per share, diluted	$ (0.21)	$ (0.23)	$ (0.44)	$ (0.51)
Weighted average number of shares, diluted	22,861,051	15,130,685	22,546,634	11,004,733

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	COMMON STOCK [Member]	ADDITIONAL PAID-IN CAPITAL [Member]	OTHER COMPREHENSIVE INCOME (LOSS) [Member]	ACCUMULATED DEFICIT [Member]	Total
Balance at Dec. 31, 2019	$ 5,227	$ 81,215,647	$ (757)	$ (74,380,731)	$ 6,839,386
Balance (in shares) at Dec. 31, 2019	5,227,398
Issuance of common stock, net of fees	$ 446	4,459,764			4,460,210
Issuance of common stock, net of fees (in shares)	444,500
Exercise of pre-funded common stock warrants	$ 3,158				3,158
Exercise of pre-funded common stock warrants (in shares)	3,158,304
Exercise of common warrants	$ 78	86,056			86,134
Exercise of common warrants (in shares)	78,304
Issuance of shares in abeyance	$ 280	(280)
Issuance of shares in abeyance (in shares)	280,000
Stock-based compensation		287,807			287,807
Unrealized gain on marketable securities			757		757
Net loss				(2,084,818)	(2,084,818)
Balance at Mar. 31, 2020	$ 9,189	86,048,994		(76,465,549)	9,592,634
Balance (in shares) at Mar. 31, 2020	9,188,506
Balance at Dec. 31, 2019	$ 5,227	81,215,647	$ (757)	(74,380,731)	6,839,386
Balance (in shares) at Dec. 31, 2019	5,227,398
Unrealized gain on marketable securities					757
Net loss					(9,479,096)
Balance at Sep. 30, 2020	$ 20,212	114,247,534		(83,859,827)	30,407,919
Balance (in shares) at Sep. 30, 2020	20,211,602
Balance at Mar. 31, 2020	$ 9,189	86,048,994		(76,465,549)	9,592,634
Balance (in shares) at Mar. 31, 2020	9,188,506
Issuance of common stock, net of fees	$ 3,060	19,492,179			19,495,239
Issuance of common stock, net of fees (in shares)	3,059,959
Exercise of common warrants	$ 4,172	5,340,016			5,344,188
Exercise of common warrants (in shares)	4,172,390
Issuance of shares in abeyance	$ 3,276	(3,276)
Issuance of shares in abeyance (in shares)	3,275,500
Stock-based compensation		704,350			704,350
Stock options exercised	$ 1	1,696			1,697
Stock options exercised (in shares)	1,221
Net loss				(3,484,154)	(3,484,154)
Balance at Jun. 30, 2020	$ 19,698	111,583,959		(79,949,703)	31,653,954
Balance (in shares) at Jun. 30, 2020	19,697,576
Issuance of common stock, net of fees	$ 343	1,952,477			1,952,820
Issuance of common stock, net of fees (in shares)	343,498
Exercise of common warrants	$ 127	193,659			193,786
Exercise of common warrants (in shares)	126,525
Stock-based compensation		486,777			486,777
Stock options exercised	$ 44	30,662			30,706
Stock options exercised (in shares)	44,003
Unrealized gain on marketable securities					0
Net loss				(3,910,124)	(3,910,124)
Balance at Sep. 30, 2020	$ 20,212	114,247,534		(83,859,827)	30,407,919
Balance (in shares) at Sep. 30, 2020	20,211,602
Balance at Dec. 31, 2020	$ 20,577	116,216,966		(88,037,759)	28,199,784
Balance (in shares) at Dec. 31, 2020	20,577,123
Issuance of common stock, net of fees	$ 2,219	12,576,307			12,578,526
Issuance of common stock, net of fees (in shares)	2,218,874
Stock-based compensation		752,962			752,962
Stock options exercised	$ 2	1,434			1,436
Stock options exercised (in shares)	1,933
Net loss				(5,151,923)	(5,151,923)
Balance at Mar. 31, 2021	$ 22,798	129,547,669		(93,189,682)	36,380,785
Balance (in shares) at Mar. 31, 2021	22,797,930
Balance at Dec. 31, 2020	$ 20,577	116,216,966		(88,037,759)	28,199,784
Balance (in shares) at Dec. 31, 2020	20,577,123
Unrealized gain on marketable securities					0
Net loss					(13,831,996)
Balance at Sep. 30, 2021	$ 24,149	138,581,576		(101,869,755)	36,735,970
Balance (in shares) at Sep. 30, 2021	24,149,155
Balance at Mar. 31, 2021	$ 22,798	129,547,669		(93,189,682)	36,380,785
Balance (in shares) at Mar. 31, 2021	22,797,930
Issuance of common stock, net of fees	$ 200	1,035,112			1,035,312
Issuance of common stock, net of fees (in shares)	200,504
Stock-based compensation		712,299			712,299
Net loss				(4,748,266)	(4,748,266)
Balance at Jun. 30, 2021	$ 22,998	131,295,080		(97,937,948)	33,380,130
Balance (in shares) at Jun. 30, 2021	22,998,434
Issuance of common stock, net of fees	$ 1,147	6,561,006			6,562,153
Issuance of common stock, net of fees (in shares)	1,146,971
Stock-based compensation		720,281			720,281
Stock options exercised	$ 4	5,209			5,213
Stock options exercised (in shares)	3,750
Unrealized gain on marketable securities					0
Net loss				(3,931,807)	(3,931,807)
Balance at Sep. 30, 2021	$ 24,149	$ 138,581,576		$ (101,869,755)	$ 36,735,970
Balance (in shares) at Sep. 30, 2021	24,149,155

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (13,831,996)	$ (9,479,096)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	167,052	101,814
Stock-based compensation	2,185,542	1,478,934
Forgiveness of debt	(318,160)	0
Change in assets - (increase) decrease:
Receivables	(180,178)	71,105
Prepaid expenses and other current assets	732,300	397,196
Other assets	(200,000)	30,907
Change in liabilities - increase (decrease):
Accounts payable and accrued expenses	263,699	1,186,727
NET CASH USED IN OPERATING ACTIVITIES	(11,181,741)	(6,212,413)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of marketable securities		(6,130,193)
Proceeds from sales and maturities of marketable securities		12,117,000
Purchases of property and equipment	(827,615)	(259,480)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(827,615)	5,727,327
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock	20,175,991	25,908,269
Proceeds from note payable		318,160
Proceeds from exercise of warrants		5,627,266
Proceeds from exercise of stock options	6,649	32,403
NET CASH PROVIDED BY FINANCING ACTIVITIES	20,182,640	31,886,098
NET INCREASE IN CASH AND CASH EQUIVALENTS	8,173,284	31,401,012
Cash and cash equivalents balance at beginning of period	32,665,874	3,899,328
Cash and cash equivalents balance at end of period	40,839,158	35,300,340
SUPPLEMENTAL DISCLOSURES:
Interest paid in cash	0	0
Income taxes paid in cash	$ 0	$ 0

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2021
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business Capricor Therapeutics, Inc., a Delaware corporation (referred to herein as “Capricor Therapeutics” or the “Company” or “we”), is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. Capricor, Inc. (“Capricor”), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marbán, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics, Inc., a Delaware corporation (“Nile”), on November 20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics, Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple active drug and vaccine candidates in various stages of development. ​ Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements for Capricor Therapeutics and its wholly-owned subsidiary have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and with the instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP. In the Company’s opinion, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation have been included. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2021, from which the December 31, 2020 consolidated balance sheet has been derived. Interim results are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. Certain reclassification of prior period amounts has been made to conform to the current year presentation. Basis of Consolidation Our condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation. Liquidity The Company has historically financed its research and development activities as well as operational expenses from equity financings, government grants, a payment from a former collaboration partner, a loan award and a grant from the California Institute for Regenerative Medicine (“CIRM”). Cash and cash equivalents as of September 30, 2021 were approximately $40.8 million, compared to approximately $32.7 million as of December 31, 2020. The Company has entered into a Common Stock Sales Agreement with H.C. Wainwright & Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company from time to time offered and sold shares of its common stock, par value $0.001 per share (see Note 3 - "Stockholders' Equity"). The Company’s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements. The Company’s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following: ● the timing and costs associated with its research and development activities, clinical trials and preclinical studies; ● the timing and costs associated with the manufacturing of its product candidates; ● the timing and costs associated with commercialization of its product candidates; ● the number and scope of its research programs; and ● the costs involved in prosecuting and enforcing patent claims and other intellectual property rights. The Company’s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential partnering opportunities, and from government grants. The Company will require substantial additional capital to fund its operations, in particular if it elects to expand its clinical programs as contemplated by its current business plan. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company’s business and results of operations. The Company would likely need to delay, curtail or terminate all or portions of its clinical trial programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution. ​ Business Uncertainty Related to the Coronavirus As a result of the COVID-19 coronavirus, uncertainties have arisen that have impacted enrollment of and the ability to conduct clinical trials, deliverables related to contract performance, workforce stability, supply chain disruptions or delays, as well as other potential business operations. While the disruption is currently expected to be temporary, there is considerable uncertainty around its expected duration and as a result, the Company is considering the impact of COVID-19 on its ability to conduct both preclinical development and clinical studies. In addition, there may be risks to the Company’s ability to obtain financing from other sources due to the impact of the coronavirus. There could be other financial impacts on our business due to the coronavirus, the specifics of which are unknown at this time. ​ In light of uncertainties due to COVID-19 and its economic and other impacts and to uncertainties around the timing and availability of grant disbursements, the loss of revenue from the delays of the REGRESS and ALPHA trials as well as any potential equity and debt financings, the Company applied for a loan under the Small Business Administration (the “SBA”) Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the “CARES Act”). On April 29, 2020, the Company was approved and received a loan of $318,160 (the “Loan”) under the SBA Paycheck Protection Program of the CARES Act (see Note 2 – “Note Payable”). ​ The Employee Retention Credit (“ERC”), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, was established by the CARES Act. The Company recorded $367,168 in ERC as other income for the three and nine months ended September 30, 2021, of which $175,969 is recorded as a receivable as of September 30, 2021. The Company may submit for additional credits under the CARES Act in the future, as applicable. ​ Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents. Marketable Securities The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company’s marketable securities are considered as available-for-sale and carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are excluded from net income (loss) and reported in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. Property and Equipment Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from five seven years Property and equipment, net consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2021 2020 Furniture and fixtures ​ $ 55,440 ​ $ 48,676 Laboratory equipment ​ 2,294,559 ​ 1,473,708 Leasehold improvements ​ 47,043 ​ 47,043 ​ ​ 2,397,042 ​ 1,569,427 Less accumulated depreciation ​ (883,467) ​ (718,580) Property and equipment, net ​ $ 1,513,575 ​ $ 850,847 ​ Intangible Assets Amounts attributable to intellectual property consist primarily of the costs associated with the acquisition of certain technologies, patents, pending patents and related intangible assets with respect to research and development activities. Certain intellectual property assets are stated at cost and amortized on a straight-line basis over the respective estimated useful lives of the assets ranging from five fifteen years ​ The Company reviews goodwill and intangible assets at least annually for possible impairment. Goodwill and intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. No impairment was recorded for the nine months ended September 30, 2021 and 2020. Leases ASC Topic 842, “Leases” (“ASC 842”), as adopted in the first quarter of 2019, requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (“ROU asset”). ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance. ​ Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. ​ The Company leases office and laboratory space, all of which are operating leases (see Note 7 - “Commitments and Contingencies”). Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company’s lease agreements generally do not contain any residual value guarantees or restrictive covenants. ​ The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ​ For real estate leases, the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only. This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements. ​ Revenue Recognition The company applies ASU 606, Revenue from Contracts with Customers Government Research Grants Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award from CIRM (the “CIRM Award’) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 6 - “Government Grant Awards”). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. Miscellaneous Income Revenue is recognized in connection with the delivery of doses which were developed as part of our past research and development (“R&D”) efforts. Income is recorded when the Company has satisfied the obligations as identified in the contracts with the customer (see Note 9 – “Related Party Transactions”). Miscellaneous income is due upon billing. Miscellaneous income is based on contracts with fixed transaction prices. Research and Development Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with Financial Accounting Standards Board (“FASB”) ASC 730-10, Research and Development Comprehensive Income (Loss) Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. The Company’s comprehensive loss was approximately $3.9 million for each of the three months ended September 30, 2021 and 2020 and approximately $13.8 million and $9.5 million for the nine months ended September 30, 2021 and 2020, respectively. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities. Clinical Trial Expense As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, and contract research organizations (“CROs”), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussion with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period. Stock-Based Compensation The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company's estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options. Basic and Diluted Loss per Share The Company reports earnings per share in accordance with FASB ASC 260-10, Earnings per Share. As of September 30, 2021 and 2020, warrants and options to purchase 3,968,546 and 2,494,068 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive common shares, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the three and nine months ended September 30, 2021 and 2020. Fair Value Measurements Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows: ​ ​ ​ ​ Level Input: Input Definition: ​ ​ ​ Level I ​ Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level II ​ Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date. Level III ​ Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. ​ Carrying amounts reported in the balance sheet of cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. Recent Accounting Pronouncements In October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

NOTE PAYABLE

NOTE PAYABLE	9 Months Ended
	Sep. 30, 2021
NOTE PAYABLE
NOTE PAYABLE	2. NOTE PAYABLE Paycheck Protection Program Loan In the second quarter of 2020, Capricor applied to City National Bank (“CNB”) under the SBA Paycheck Protection Program of the CARES Act for the Loan in the amount of $318,160. The Loan was approved and Capricor received the Loan proceeds, which were used for covered payroll costs in accordance with the relevant terms and conditions of the CARES Act. The Loan, which took the form of a promissory note issued by Capricor (the “Promissory Note”), had a two-year bankruptcy, breaches of representations and material adverse events. Capricor had the right to prepay the principal of the Loan at any time without incurring any prepayment charges. The Company submitted a loan forgiveness application to CNB in the first quarter of 2021. The Company was notified in April 2021 by the SBA that the Loan was forgiven. The Company recognized a gain on forgiveness in the second quarter of 2021.

STOCKHOLDER'S EQUITY

STOCKHOLDER'S EQUITY	9 Months Ended
	Sep. 30, 2021
STOCKHOLDER'S EQUITY
STOCKHOLDER'S EQUITY	3. STOCKHOLDER’S EQUITY ATM Programs and Other Offerings The Company has established multiple “at-the-market” (“ATM”), programs pursuant to a Common Stock Sales Agreement with Wainwright by which Wainwright sold and may continue to sell our common stock at the market prices prevailing at the time of sale. Wainwright is entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold plus reimbursement of certain expenses. These programs are referred to below as the “August 2019 ATM Program,” the “May 2020 ATM Program,” and the “June 2021 ATM Program” based on when each program was initiated. In addition, the Company completed a public offering of its common stock in December 2019 and a warrant inducement offer in March 2020. August 2019 ATM Program On August 29, 2019, the Company initiated the August 2019 ATM Program. From August 29, 2019 through May 4, 2020, the Company sold an aggregate of 360,316 shares of common stock under the August 2019 ATM Program at an average price of approximately $3.07 per share for gross proceeds of approximately $1.1 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $0.1 million. As of May 4, 2020, the August 2019 ATM Program expired and was replaced with the May 2020 ATM Program described below. May 2020 ATM Program On May 4, 2020, the Company initiated the May 2020 ATM Program. The Company filed the May 2020 ATM with an aggregate offering price of up to $40.0 million. From May 4, 2020 through June 21, 2021, the Company sold an aggregate of 6,027,852 shares of common stock under the May 2020 ATM Program at an average price of approximately $6.15 per share for gross proceeds of approximately $37.1 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $1.2 million. As of June 21, 2021, the May 2020 ATM Program expired and was replaced with the June 2021 ATM Program described below. June 2021 ATM Program On June 21, 2021, the Company initiated the June 2021 ATM Program. The Company filed the June 2021 ATM with an aggregate offering price of up to $75.0 million. From June 21, 2021 through September 30, 2021, the Company sold an aggregate of 1,267,475 shares of common stock under the June 2021 ATM Program at an average price of approximately $5.89 per share for gross proceeds of approximately $7.5 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $0.3 million. December 2019 Financing In December 2019, the Company completed a public offering pursuant to which the Company issued (i) 531,173 shares of its common stock, (ii) warrants (the “December 2019 Common Warrants”) to purchase up to 4,139,477 shares of common stock, and (iii) pre-funded warrants to purchase up to 3,608,304 shares of common stock, at a combined purchase price of $1.226 per share and associated December 2019 Common Warrant and $1.225 per pre-funded warrant and associated December 2019 Common Warrant, for an aggregate purchase price of approximately $5.1 million. The Company issued (a) to each purchaser of shares in the offering a December 2019 Common Warrant to purchase a number of shares of common stock equal to the number of shares purchased by such purchaser in the offering, and (b) to each purchaser of pre-funded warrants in the offering a December 2019 Common Warrant to purchase a number of shares of common stock equal to the number of pre-funded warrant shares underlying the pre-funded warrants purchased by such purchaser in the offering. In connection with the offering, the Company issued to designees of Wainwright, the placement agent for the offering, warrants (the "December 2019 Placement Agent Warrants") to purchase an aggregate of 203,915 shares of common stock. The December 2019 Placement Agent Warrants have an exercise price of $1.5325 per share, are immediately exercisable and expire in December 2024. Fees paid in conjunction with the deal, which included placement agent commissions, management fees, legal costs, and other offering expenses, amounted to approximately $0.7 million in the aggregate and were recorded as a reduction to additional paid-in capital, resulting in net proceeds of approximately $4.4 million. As of September 30, 2021, 61,173 December 2019 Common Warrants remained outstanding under the December 2019 Financing. March 2020 Warrant Inducement On March 25, 2020, the Company entered into a letter agreement (the "Exercise Agreement") with a holder of December 2019 Common Warrants (the "Exercising Holder"). Pursuant to the Exercise Agreement, in connection with the exercise by the Exercising Holder of the remaining 4,000,000 December 2019 Common Warrants held by the Exercising Holder which had not been previously exercised, the Company agreed to issue 4,000,000 additional warrants (the "New Warrants") to purchase Common Stock. The December 2019 Common Warrants had a per share exercise price of $1.10, and pursuant to the Exercise Agreement, the Exercising Holder agreed to pay $1.225 per share to cover both the exercise price of the December 2019 Common Warrants and a $0.125 per share purchase price for the New Warrants. The New Warrants have an exercise price of $1.27 per share. A total of 724,500 shares were issued to the Exercising Holder, with the remaining 3,275,500 shares being held in abeyance until such time as it would not result in the Exercising Holder exceeding its beneficial ownership limitation of 4.99% of the Company's outstanding common stock. In the second quarter of 2020, the Company issued all shares that were being held in abeyance. The New Warrants and the shares of Common Stock issuable upon the exercise of the New Warrants were not registered under the Securities Act of 1933, as amended (the "Securities Act"), and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act or Rule 506(b) promulgated thereunder. The New Warrants are exercisable immediately upon issuance and have a term of exercise of 5 1/2 The exercise of December 2019 Common Warrants by the Exercising Holder generated gross proceeds of approximately $4.9 million. Fees paid in conjunction with the Exercise Agreement, which included placement agent commissions, legal costs, and other offering expenses, amounted to approximately $0.4 million. In connection with the Exercise Agreement, certain employees of the placement agent were issued new warrants (the "March 2020 Placement Agent Warrants") to purchase an aggregate of 200,000 shares of common stock. The March 2020 Placement Agent Warrants have an exercise price of $1.5313 per share and expire in March 2025. The holders of each of the New Warrants and of the March 2020 Placement Agent Warrants have the option to make a cashless exercise of such warrant if no resale registration statement covering the shares of the Company's Common Stock underlying such warrant is effective after six months Outstanding Shares At September 30, 2021, the Company had 24,149,155 shares of common stock issued and outstanding

STOCK AWARDS, WARRANTS AND OPTI

STOCK AWARDS, WARRANTS AND OPTIONS	9 Months Ended
	Sep. 30, 2021
STOCK AWARDS, WARRANTS AND OPTIONS
STOCK AWARDS, WARRANTS AND OPTIONS	4. STOCK AWARDS, WARRANTS AND OPTIONS Warrants The following table summarizes all warrant activity for the nine months ended September 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Warrants Exercise Price Outstanding at December 31, 2020 126,173 ​ $ 1.32 Granted ​ — ​ ​ — Exercised ​ — ​ ​ — Outstanding at September 30, 2021 126,173 ​ $ 1.32 ​ The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Outstanding ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ Exercise Price ​ Expiration Type Grant Date 2021 2020 per Share Date ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common Warrants ​ 12/19/2019 ​ 61,173 61,173 ​ $ 1.10 ​ 12/19/2024 Common Warrants ​ 3/27/2020 ​ 65,000 65,000 ​ $ 1.5313 ​ 3/27/2025 ​ ​ ​ ​ 126,173 ​ 126,173 ​ ​ ​ ​ ​ ​ Stock Options The Company’s Board of Directors (the “Board”) has approved five stock option plans: (i) the 2006 Stock Option Plan, (ii) the 2012 Restated Equity Incentive Plan (which superseded the 2006 Stock Option Plan) (the “2012 Plan”), (iii) the 2012 Non-Employee Director Stock Option Plan (the “2012 Non-Employee Director Plan”), (iv) the 2020 Equity Incentive Plan (the “2020 Plan”), and (v) the 2021 Equity Incentive Plan (the “2021 Plan”). At the time of the merger between Capricor and Nile became effective, 414,971 shares of common stock were reserved under the 2012 Plan for the issuance of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and other service providers. Included in the 2012 Plan are the shares of common stock that were originally reserved under the 2006 Stock Option Plan. Under the 2012 Plan, each stock option granted will be designated in the award agreement as either an incentive stock option or a nonstatutory stock option. Notwithstanding such designation, however, to the extent that the aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by the participant during any calendar year (under all plans of the Company and any parent or subsidiary) exceeds $100,000, such options will be treated as nonstatutory stock options. On June 2, 2016, at the Company’s annual stockholder meeting, the stockholders approved a proposal to amend the 2012 Plan, to, among other things, increase the number of shares of common stock of the Company that may be issued under the 2012 Plan to equal the sum of 414,971 plus 2% of the outstanding shares of common stock as of December 31, 2015, with the number of shares that may be issued under the 2012 Plan automatically increasing thereafter on January 1 of each year, commencing with January 1, 2017, by 2% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year (rounded down to the nearest whole share). For the fiscal years beginning on January 1, 2020 and 2019, the number of shares added was 104,547 and 62,775 shares, respectively. At the time of the merger between Capricor and Nile became effective, 269,731 shares of common stock were reserved under the 2012 Non-Employee Director Plan for the issuance of stock options to members of the Board who are not employees of the Company. On June 5, 2020, at the Company’s annual stockholder meeting, the stockholders approved the 2020 Plan with 2,500,000 shares of common stock reserved under the 2020 Plan for the issuance of stock awards. The number of shares available for issuance under the 2020 Plan shall be automatically increased on January 1 of each year, commencing with January 1, 2021, by an amount equal to the lesser of (i) 4% of the outstanding shares of Common Stock as of the last day of the immediately preceding fiscal year or (ii) such number of shares of Common Stock determined by the Compensation Committee in its sole discretion. For the fiscal year beginning on January 1, 2021, the number of shares added was 823,084 shares. Upon approval of the 2021 Plan on June 11, 2021, no new shares have been or will be added to the share reserve under the 2020 Plan pursuant to its “evergreen” provisions. On June 11, 2021, at the Company’s annual stockholder meeting, the stockholders approved the 2021 Plan with 3,500,000 shares of common stock reserved under the 2021 Plan for the issuance of stock awards. The number of shares available for issuance under the 2021 Plan shall be automatically increased on January 1 of each year, commencing with January 1, 2022, by an amount equal to 5% of the outstanding shares of Common Stock as of the last day of the immediately preceding fiscal year. As of September 30, 2021, 3,836,588 options remain available for issuance under the respective stock option plans. Each of the Company’s stock option plans are administered by the Board, or the compensation committee of the Board, which determines the recipients and types of awards to be granted, as well as the number of shares subject to the awards, the exercise price and the vesting schedule. Stock options are granted with an exercise price equal to the closing price of the Company’s common stock on the date of grant, and generally vest over a period of one four years ten years The estimated weighted average fair value of the options granted during the three months ended September 30, 2021 and 2020 were approximately $4.03 and $5.23 per share, respectively. The estimated weighted average fair value of the options granted during the nine months ended September 30, 2021 and 2020 were approximately $3.40 and $3.91 per share, respectively. The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions to estimate the fair value of stock options issued in the nine months ended September 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 September 30, 2020 Expected volatility 123% - 124 % 104% - 123 % Expected term 6 years 5 6 years ​ Dividend yield 0 % 0 % Risk-free interest rates 0.5 - 1.1 % 0.4 - 1.5 % ​ Employee and non-employee stock-based compensation expense was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended September 30, ​ Nine months ended September 30, ​ ​ 2021 2020 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ General and administrative ​ $ 654,744 ​ $ 418,147 ​ $ 1,913,005 ​ $ 1,287,474 ​ Research and development ​ 65,537 ​ 68,630 ​ 272,537 ​ 191,460 ​ Total ​ $ 720,281 ​ $ 486,777 ​ $ 2,185,542 ​ $ 1,478,934 ​ ​ The Company does not recognize an income tax benefit as the Company believes that an actual income tax benefit may not be realized. For non-qualified stock options, the loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. Common stock, stock options or other equity instruments issued to non-employees (including consultants) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company calculates the fair value for non-qualified options as of the date of grant and expenses over the applicable vesting periods. We account for forfeitures upon occurrence. As of September 30, 2021, the total unrecognized fair value compensation cost related to non-vested stock options was approximately $8.5 million, which is expected to be recognized over a weighted average period of approximately 1.5 years. ​ The following is a schedule summarizing employee and non-employee stock option activity for the nine months ended September 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ Weighted Average ​ Aggregate ​ Options Exercise Price Intrinsic Value Outstanding at December 31, 2020 2,361,873 ​ $ 1.89 $ 4,236,737 Granted 1,636,324 ​ 3.95 ​ Exercised (5,883) ​ 1.39 $ 22,761 Expired/Cancelled (149,941) ​ 3.89 ​ Outstanding at September 30, 2021 3,842,373 ​ $ 2.69 ​ $ 5,737,004 Exercisable at September 30, 2021 1,454,788 ​ $ 1.92 ​ $ 3,161,020 ​ The aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock for each of the respective periods.

CONCENTRATIONS

CONCENTRATIONS	9 Months Ended
	Sep. 30, 2021
CONCENTRATIONS
CONCENTRATIONS	5. CONCENTRATIONS Cash Concentration The Company has historically maintained checking accounts at two financial institutions. These accounts are each insured by the Federal Deposit Insurance Corporation for up to $250,000. Historically, the Company has not experienced any significant losses in such accounts and believes it is not exposed to any significant credit risk on cash, cash equivalents and marketable securities. As of September 30, 2021, the Company maintained approximately $40.6 million of uninsured deposits.

GOVERNMENT GRANT AWARDS

GOVERNMENT GRANT AWARDS	9 Months Ended
	Sep. 30, 2021
GOVERNMENT GRANT AWARDS
GOVERNMENT GRANT AWARDS	6. GOVERNMENT GRANT AWARDS CIRM Grant Award (HOPE) On June 16, 2016, Capricor entered into the CIRM Award with CIRM in the amount of approximately $3.4 million to fund, in part, Capricor’s Phase I/II HOPE-Duchenne clinical trial investigating CAP-1002 for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy. Pursuant to terms of the CIRM Award, the disbursements were tied to the achievement of specified operational milestones. In addition, the terms of the CIRM Award included a co-funding requirement pursuant to which Capricor was required to spend approximately $2.3 million of its own capital to fund the CIRM funded research project. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600-100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section 100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to nine times the total amount awarded and paid to Capricor. After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-year anniversary of the date of the award), Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and development of the program at the time the election is made. On June 20, 2016, Capricor entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten-year anniversary of the grant date of the CIRM Award. Beginning on the date of the loan, the loan shall bear interest on the unpaid principal balance, plus the interest that has accrued prior to the election point according to the terms set forth in CIRM’s Loan Policy (the “New Loan Balance”), at a per annum rate equal to the LIBOR rate for a three-month deposit in U.S. dollars, as published by the Wall Street Journal on the loan date, plus one percent. Interest shall be compounded annually on the outstanding New Loan Balance commencing with the loan date and the interest shall be payable, together with the New Loan Balance, upon the due date of the loan. If Capricor elects to convert the CIRM Award into a loan, certain requirements of the CIRM Award will no longer be applicable, including the revenue sharing requirements. Capricor has not yet made its decision as to whether it will elect to convert the CIRM Award into a loan. If we elect to do so, Capricor would be required to repay some or all of the amounts awarded by CIRM; therefore, the Company accounts for this award as a liability rather than income. In June 2019, Capricor completed all milestones associated with the CIRM Award and expended all funds received. In the third quarter of 2019, Capricor completed all final close-out documentation associated with this award. As of September 30, 2021, Capricor’s liability balance for the CIRM Award was approximately $3.4 million. U.S. Department of Defense Grant Award In September 2016, Capricor was approved for a grant award from the Department of Defense in the amount of approximately $2.4 million to be used toward developing a scalable, commercial-ready process to manufacture CAP-2003, Capricor’s exosomes product candidate. Under the terms of the award, disbursements were made to Capricor over a period of approximately four years, subject to annual and quarterly reporting requirements. The Company utilized approximately $2.3 million under the terms of the award. No revenue was recognized in 2021 in relation to this award. In the third quarter of 2021, Capricor completed all final close-out documentation associated with this award.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	7. COMMITMENTS AND CONTINGENCIES Leases Capricor leases space for its corporate offices from The Bubble Real Estate Company, LLC ("Bubble Real Estate") pursuant to a lease that was originally effective for a two-year period beginning July 1, 2013 with an option to extend the lease for an additional twelve months. Capricor subsequently entered into several amendments extending the term of the lease and modifying its terms. Effective January 1, 2021, we entered into a month-to-month lease amendment with the Bubble Real Estate. The monthly lease payment was $13,073. In November 2021, Capricor entered into an amendment to the lease pursuant to which the square footage of the premises was reduced with a monthly lease payment of $5,548 per month commencing November 1, 2021. The lease is terminable by either party upon 90 days’ written notice to the other party. Capricor leases facilities from CSMC, a related party (see Note 9 – “Related Party Transactions”), pursuant to a lease (the “Facilities Lease”) that was originally effective for a three-year period beginning June 1, 2014. Capricor has subsequently entered into several amendments extending the term of the lease and modifying its terms. In July 2020, Capricor exercised its option to extend the term of the Facilities Lease for an additional 12-month period through July 31, 2021 with a monthly lease payment of $15,805. The Company has a further option to extend the Facilities Lease with respect to a portion of the leased premises through July 31, 2022 with a monthly lease payment of $10,707. In July 2021, the Company notified CSMC that it was exercising this option. On July 16, 2021, the Company entered into a lease agreement with Altman Investment Co, LLC (“Altman”) for 9,396 square feet of office and laboratory space located at 10865 Road to the Cure, Suite 150, in San Diego, California. Under the terms of the lease, the base rent will be approximately $0.6 million per year, which rent is subject to a 3.0% annual rent increase during the initial lease term, plus certain operating expenses and taxes. This lease term commenced on October 1, 2021 and will expire on October 15, 2026. The lease contains an option for Capricor to renew for an additional term of five years. The Company estimates the aggregate ROU asset and liability to be approximately $2.7 million relating to this lease as of the commencement date of October 1, 2021 Included within the table below, future minimum rental payments to related parties totaled $107,066. A summary of future minimum rental payments required under operating leases as of September 30, 2021 is as follows: ​ ​ ​ ​ ​ Years ended Operating Leases 2021 (3 month) ​ $ 32,120 2022 ​ ​ 74,946 ​ The above table excludes the commitments associated with the ROU lease liabilities in connection with our operating leases. Legal Contingencies The Company is not a party to any material legal proceedings at this time. From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business or otherwise. Accounts Payable During the normal course of business, disputes with vendors may arise. If a vendor disputed payment is probable and able to be estimated, we will record an estimated liability. Other Funding Commitments The Company is a party to various agreements, principally relating to licensed technology, that require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specific products (see Note 8 – “License Agreements”). Additionally, the Company is a party to various agreements with contract research organizations and contract manufacturers that generally provide for termination upon notice, with the exact amounts owed in the event of termination to be based on the timing of termination and the terms of the agreement. Employee Severances The Board of Directors approved severance packages for specific full-time employees based on their length of service and position ranging up to six months of their base salaries, in the event of termination of their employment, subject to certain conditions. No liability has been recorded as of September 30, 2021.

LICENSE AGREEMENTS

LICENSE AGREEMENTS	9 Months Ended
	Sep. 30, 2021
LICENSE AGREEMENTS
LICENSE AGREEMENTS	8. LICENSE AGREEMENTS Capricor’s Technology - CAP-1002 and Exosomes Capricor has entered into exclusive license agreements for intellectual property rights related to certain cardiac-derived cells with Università Degli Studi Di Roma La Sapienza (the “University of Rome”), Johns Hopkins University (“JHU”) and CSMC. Capricor has also entered into an exclusive license agreement for intellectual property rights related to exosomes with CSMC and JHU as well as a non-exclusive license agreement with JHU related to the imaging-based serology technology for COVID-19. In addition, Capricor has filed patent applications related to the technology developed by its own scientists. University of Rome License Agreement Capricor and the University of Rome entered into a License Agreement, dated June 21, 2006 (the “Rome License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by the University of Rome to Capricor (with the right to sublicense) to develop and commercialize licensed products under the licensed patent rights in all fields. Capricor has a right of first negotiation, for a certain period of time, to obtain a license to any new and separate patent applications owned by the University of Rome utilizing cardiac stem cells in cardiac care. Pursuant to the Rome License Agreement, Capricor paid the University of Rome a license issue fee, is currently paying minimum annual royalties in the amount of 20,000 Euros per year and is obligated to pay a lower-end of a mid-range double-digit percentage on all royalties received as a result of sublicenses granted, which are net of any royalties paid to third parties under a license agreement from such third party to Capricor. The minimum annual royalties are creditable against future royalty payments. The Rome License Agreement will, unless extended or sooner terminated, remain in effect until the later of the last claim of any patent or until any patent application comprising licensed patent rights has expired or been abandoned. Under the terms of the Rome License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy. Either party may terminate the agreement upon the other party’s material breach, provided that the breaching party will have up to 90 days to cure its material breach. Capricor may also terminate for any reason upon 90 days’ written notice to the University of Rome. The Johns Hopkins University License Agreements License Agreement for CDCs Capricor and JHU entered into an Exclusive License Agreement, effective June 22, 2006 (the “JHU License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by JHU to Capricor (with the right to sublicense) to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how. In May 2009, the JHU License Agreement was amended to add additional patent rights to the JHU License Agreement in consideration of a payment to JHU and reimbursement of patent costs. Capricor and JHU executed a Second Amendment to the JHU License Agreement, effective as of December 20, 2013, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified. Under the JHU License Agreement, Capricor is required to exercise commercially reasonable and diligent efforts to develop and commercialize licensed products covered by the licenses from JHU. Pursuant to the JHU License Agreement, JHU was paid an initial license fee and, thereafter, Capricor is required to pay minimum annual royalties on the anniversary dates of the JHU License Agreement. The minimum annual royalties are creditable against a low single-digit running royalty on net sales of products and net service revenues, which Capricor is also required to pay under the JHU License Agreement, which running royalty may be subject to further reduction in the event that Capricor is required to pay royalties on any patent rights to third parties in order to make or sell a licensed product. In addition, Capricor is required to pay a low double-digit percentage of the consideration received by it from sublicenses granted, and is required to pay JHU certain defined development milestone payments upon the successful completion of certain phases of its clinical studies and upon receiving approval from the U.S. Food and Drug Administration (the “FDA”). The development milestones range from $100,000 upon successful completion of a full Phase I clinical study to $1,000,000 upon full FDA market approval and are fully creditable against payments owed by Capricor to JHU on account of sublicense consideration attributable to milestone payments received from a sublicensee. The maximum aggregate amount of milestone payments payable under the JHU License Agreement, as amended, is $1,850,000. In May 2015, Capricor paid the development milestone related to the Phase I study that was owed to JHU pursuant to the terms of the JHU License Agreement. The next milestone is triggered upon successful completion of a full Phase II study for which a payment of $250,000 will be due. At this time, it is anticipated the $250,000 milestone payment will become due, and the amount has been included in accounts payable and accrued expenses as of September 30, 2021. The JHU License Agreement will, unless sooner terminated, continue in effect in each applicable country until the date of expiration of the last to expire patent within the patent rights, or, if no patents are issued, then for twenty years from the effective date. Under the terms of the JHU License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy, or fail to cure a material breach within 30 days after notice. In addition, Capricor may terminate for any reason upon 60 days’ written notice. License Agreement for Serology Diagnostic Capricor and JHU entered into a Nonexclusive License Agreement (the “JHU Serology License Agreement”), effective January 6, 2021, which provides for the grant of a non-exclusive, world-wide, non-royalty-bearing license by JHU to Capricor to develop and commercialize licensed products under the licensed patent rights for COVID-19. License Agreement for Exosome-based Vaccines and Therapeutics Capricor and JHU entered into an Exclusive License Agreement (the “JHU Exosome License Agreement”) effective April 28, 2021 for its co-owned interest in certain intellectual property rights related to exosome-mRNA vaccines and therapeutics. The JHU Exosome License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license of JHU’s co-owned rights by JHU to Capricor, with the right to sublicense, in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. Pursuant to the JHU Exosome License Agreement, JHU was paid an upfront license fee of $10,000 and Capricor has agreed to reimburse JHU for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain development milestones for which a milestone payment fee shall be due and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a double-digit percentage of any non-royalty consideration received from any sublicenses, subject to certain exclusions. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to pay royalties on one or more third party patents as a requirement to make or sell a licensed product. In addition, Capricor will, beginning with the third year of the JHU Exosome License Agreement, be obligated to pay JHU a minimum annual royalty which is non-refundable but will be credited against royalties incurred by Capricor for the year in which the minimum annual royalty becomes due. The JHU Exosome License Agreement will, unless sooner terminated, continue in each country until the date of expiration of the last to expire patent included within the patent rights in that country, or if no patents issue, then for 20 years. The JHU Exosome License Agreement may be terminated by Capricor upon 90 days’ written notice in its discretion and with 60 days’ notice with respect to any particular patent or application or as to any particular licensed product. The JHU Exosome License Agreement may also be terminated by either party if it fails to perform or otherwise breaches any of its obligations and fails to cure such breach within a 60-day Cedars-Sinai Medical Center License Agreements License Agreement for CDCs On January 4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the “Original CSMC License Agreement”), for certain intellectual property related to its CDC technology. In 2013, the Original CSMC License Agreement was amended twice resulting in, among other things, a reduction in the percentage of sublicense fees which would have been payable to CSMC. Effective December 30, 2013, Capricor entered into an Amended and Restated Exclusive License Agreement with CSMC (the “Amended CSMC License Agreement”), which amended, restated, and superseded the Original CSMC License Agreement, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified. The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) to conduct research using the patent rights and know-how and develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license for any future rights, Capricor will have a non-exclusive license to such future rights, subject to royalty obligations. Pursuant to the Original CSMC License Agreement, CSMC was paid a license fee and Capricor was obligated to reimburse CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain spending and development milestones. Pursuant to the Amended CSMC License Agreement, Capricor remains obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a low double-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third party for patent rights in connection with the royalty-bearing product. In 2010, Capricor discontinued its research under some of the patents. The Amended CSMC License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Amended CSMC License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) after 90 days’ notice from CSMC if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after 90 days’ notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice. On March 20, 2015, August 5, 2016, December 26, 2017, June 20, 2018, and July 27, 2021, Capricor and CSMC entered into a number of amendments to the Amended CSMC License Agreement, pursuant to which the parties agreed to add and delete certain patent applications from the list of scheduled patents, among other things. Capricor reimbursed CSMC for certain attorneys’ fees and filing fees incurred in connection with the additional patent applications. License Agreement for Exosomes On May 5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the “Exosomes License Agreement”), for certain intellectual property rights related to exosomes technology. The Exosomes License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations. Pursuant to the Exosomes License Agreement, CSMC was paid a license fee and Capricor reimbursed CSMC for certain fees and costs incurred in connection with the preparation and prosecution of certain patent applications. Additionally, Capricor is required to meet certain non-monetary development milestones and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a single-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third party for patent rights in connection with the royalty bearing product. The Exosomes License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Exosomes License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) after 90 days if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after 90 days’ notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice. On February 27, 2015, June 10, 2015, August 5, 2016, December 26, 2017, June 20, 2018, September 25, 2018, August 19, 2020, August 28, 2020, and March 19, 2021, Capricor and CSMC entered into a number of amendments to the Exosomes License Agreement. Collectively, these amendments added additional patent applications and patent families to the Exosomes License Agreement, added certain defined product development milestone payments, modified certain milestone deadlines, and added certain performance milestones with respect to product candidates covered by certain future patent rights in order to maintain an exclusive license to those future patent rights; failure to meet those milestones would cause CSMC to have the right to convert the license from exclusive to non-exclusive or co-exclusive, or to terminate the license, subject to Capricor’s right to license such patent rights for internal research purposes on a non-exclusive basis. These amendments also obligated Capricor to reimburse CSMC for certain attorneys’ fees and filing fees in connection with the additional patent applications and patent families. Sponsored Research Agreement with Johns Hopkins University On April 1, 2020 we entered into a Sponsored Research Agreement (the “SRA”), with JHU pursuant to which researchers in the lab of Dr. Stephen Gould are performing certain research activities in connection with our exosomes program. Pursuant to the SRA, we are funding certain research activities and have the right to negotiate for exclusive or non-exclusive rights to intellectual property that may result from such research activities.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2021
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	9. RELATED PARTY TRANSACTIONS Lease and Sub-Lease Agreement As noted above, Capricor is a party to lease agreements with CSMC (see Note 7 – “Commitments and Contingencies”), and CSMC has served as an investigative site in Capricor’s clinical trials. Additionally, Dr. Eduardo Marbán, who is a stockholder of Capricor Therapeutics and has participated from time to time as an observer at the Company’s meetings of the Board of Directors, is the Director of the Cedars-Sinai Smidt Heart Institute, and co-founder of Capricor. On April 1, 2013, Capricor entered into a sublease with Reprise Technologies, LLC, a limited liability company which is wholly owned by Dr. Frank Litvack, the Company’s Executive Chairman and member of its Board of Directors, for $2,500 per month. The sublease was on a month-to-month basis and was terminated effective September 1, 2020. For the nine months ended September 30, 2021 and 2020, Capricor recognized zero and $20,000, respectively, in sublease income from the related party. Sublease income is recorded as a reduction to general and administrative expenses. Consulting Agreements In 2013, Capricor entered into a Consulting Agreement with Dr. Frank Litvack, the Company’s Executive Chairman and a member of its Board of Directors, whereby Capricor agreed to pay Dr. Litvack $10,000 per month for consulting services. The agreement is terminable upon 30 days’ notice. Payables to Related Party As of September 30, 2021 and December 31, 2020, the Company had accounts payable and accrued expenses to related parties totaling $497,080 and $8,972, respectively, which were fully due to CSMC. CSMC expenses relate to research and development costs, clinical trial costs, license and patent fees, and facilities rent. During the nine months ended September 30, 2021 and 2020, the Company paid CSMC approximately $292,400 and $235,000, respectively, for such costs. Related Party Clinical Trials Capricor provided CAP-1002 for investigational purposes in two clinical trials sponsored by CSMC. This product was developed as part of the Company’s past research and development efforts. The first trial is known as “Regression of Fibrosis and Reversal of Diastolic Dysfunction in HFpEF Patients Treated with Allogeneic CDCs”, or REGRESS. Dr. Eduardo Marbán is the named principal investigator under the study. The second trial is known as “Pulmonary Arterial Hypertension treated with Cardiosphere-derived Allogeneic Stem Cells” or ALPHA. In both studies, Capricor provided the necessary number of doses of cells and received a total of approximately $1.7 million of monetary compensation. For the nine months ended September 30, 2021 and 2020, the Company recognized approximately $245,000 and $67,000, respectively, as revenue. As of September 30, 2021, and December 31, 2020, zero and approximately $56,000, respectively, is outstanding and recorded in prepaid expenses and other current assets. CSMC informed us that the enrollment of the REGRESS and ALPHA studies have been completed and as a result, we do not expect to receive any further material revenues from these trials.

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2021
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements for Capricor Therapeutics and its wholly-owned subsidiary have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and with the instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP. In the Company’s opinion, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation have been included. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2021, from which the December 31, 2020 consolidated balance sheet has been derived. Interim results are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. Certain reclassification of prior period amounts has been made to conform to the current year presentation.
Basis of Consolidation	Basis of Consolidation Our condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.
Liquidity	Liquidity The Company has historically financed its research and development activities as well as operational expenses from equity financings, government grants, a payment from a former collaboration partner, a loan award and a grant from the California Institute for Regenerative Medicine (“CIRM”). Cash and cash equivalents as of September 30, 2021 were approximately $40.8 million, compared to approximately $32.7 million as of December 31, 2020. The Company has entered into a Common Stock Sales Agreement with H.C. Wainwright & Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company from time to time offered and sold shares of its common stock, par value $0.001 per share (see Note 3 - "Stockholders' Equity"). The Company’s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements. The Company’s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following: ● the timing and costs associated with its research and development activities, clinical trials and preclinical studies; ● the timing and costs associated with the manufacturing of its product candidates; ● the timing and costs associated with commercialization of its product candidates; ● the number and scope of its research programs; and ● the costs involved in prosecuting and enforcing patent claims and other intellectual property rights. The Company’s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential partnering opportunities, and from government grants. The Company will require substantial additional capital to fund its operations, in particular if it elects to expand its clinical programs as contemplated by its current business plan. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company’s business and results of operations. The Company would likely need to delay, curtail or terminate all or portions of its clinical trial programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.
Business Uncertainty Related to the Coronavirus	Business Uncertainty Related to the Coronavirus As a result of the COVID-19 coronavirus, uncertainties have arisen that have impacted enrollment of and the ability to conduct clinical trials, deliverables related to contract performance, workforce stability, supply chain disruptions or delays, as well as other potential business operations. While the disruption is currently expected to be temporary, there is considerable uncertainty around its expected duration and as a result, the Company is considering the impact of COVID-19 on its ability to conduct both preclinical development and clinical studies. In addition, there may be risks to the Company’s ability to obtain financing from other sources due to the impact of the coronavirus. There could be other financial impacts on our business due to the coronavirus, the specifics of which are unknown at this time. ​ In light of uncertainties due to COVID-19 and its economic and other impacts and to uncertainties around the timing and availability of grant disbursements, the loss of revenue from the delays of the REGRESS and ALPHA trials as well as any potential equity and debt financings, the Company applied for a loan under the Small Business Administration (the “SBA”) Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the “CARES Act”). On April 29, 2020, the Company was approved and received a loan of $318,160 (the “Loan”) under the SBA Paycheck Protection Program of the CARES Act (see Note 2 – “Note Payable”). ​ The Employee Retention Credit (“ERC”), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, was established by the CARES Act. The Company recorded $367,168 in ERC as other income for the three and nine months ended September 30, 2021, of which $175,969 is recorded as a receivable as of September 30, 2021. The Company may submit for additional credits under the CARES Act in the future, as applicable.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.
Marketable Securities	Marketable Securities The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company’s marketable securities are considered as available-for-sale and carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are excluded from net income (loss) and reported in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from five seven years Property and equipment, net consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2021 2020 Furniture and fixtures ​ $ 55,440 ​ $ 48,676 Laboratory equipment ​ 2,294,559 ​ 1,473,708 Leasehold improvements ​ 47,043 ​ 47,043 ​ ​ 2,397,042 ​ 1,569,427 Less accumulated depreciation ​ (883,467) ​ (718,580) Property and equipment, net ​ $ 1,513,575 ​ $ 850,847 ​
Intangible Assets	Intangible Assets Amounts attributable to intellectual property consist primarily of the costs associated with the acquisition of certain technologies, patents, pending patents and related intangible assets with respect to research and development activities. Certain intellectual property assets are stated at cost and amortized on a straight-line basis over the respective estimated useful lives of the assets ranging from five fifteen years ​ The Company reviews goodwill and intangible assets at least annually for possible impairment. Goodwill and intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. No impairment was recorded for the nine months ended September 30, 2021 and 2020.
Leases	Leases ASC Topic 842, “Leases” (“ASC 842”), as adopted in the first quarter of 2019, requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (“ROU asset”). ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance. ​ Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. ​ The Company leases office and laboratory space, all of which are operating leases (see Note 7 - “Commitments and Contingencies”). Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company’s lease agreements generally do not contain any residual value guarantees or restrictive covenants. ​ The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ​ For real estate leases, the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only. This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.
Revenue Recognition	Revenue Recognition The company applies ASU 606, Revenue from Contracts with Customers Government Research Grants Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award from CIRM (the “CIRM Award’) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 6 - “Government Grant Awards”). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. Miscellaneous Income Revenue is recognized in connection with the delivery of doses which were developed as part of our past research and development (“R&D”) efforts. Income is recorded when the Company has satisfied the obligations as identified in the contracts with the customer (see Note 9 – “Related Party Transactions”). Miscellaneous income is due upon billing. Miscellaneous income is based on contracts with fixed transaction prices.
Research and Development	Research and Development Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with Financial Accounting Standards Board (“FASB”) ASC 730-10, Research and Development
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. The Company’s comprehensive loss was approximately $3.9 million for each of the three months ended September 30, 2021 and 2020 and approximately $13.8 million and $9.5 million for the nine months ended September 30, 2021 and 2020, respectively. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities.
Clinical Trail Expense	Clinical Trial Expense As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, and contract research organizations (“CROs”), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussion with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company's estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.
Basic and Diluted Loss per Share	Basic and Diluted Loss per Share The Company reports earnings per share in accordance with FASB ASC 260-10, Earnings per Share. As of September 30, 2021 and 2020, warrants and options to purchase 3,968,546 and 2,494,068 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive common shares, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the three and nine months ended September 30, 2021 and 2020.
Fair Value Measurements	Fair Value Measurements Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows: ​ ​ ​ ​ Level Input: Input Definition: ​ ​ ​ Level I ​ Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level II ​ Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date. Level III ​ Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. ​ Carrying amounts reported in the balance sheet of cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2021
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of property, plant and equipment	Property and equipment, net consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ 2021 2020 Furniture and fixtures ​ $ 55,440 ​ $ 48,676 Laboratory equipment ​ 2,294,559 ​ 1,473,708 Leasehold improvements ​ 47,043 ​ 47,043 ​ ​ 2,397,042 ​ 1,569,427 Less accumulated depreciation ​ (883,467) ​ (718,580) Property and equipment, net ​ $ 1,513,575 ​ $ 850,847

STOCK AWARDS, WARRANTS AND OP_2

STOCK AWARDS, WARRANTS AND OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2021
Warrant [Member]
Summary of warrant activity	The following table summarizes all warrant activity for the nine months ended September 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Warrants Exercise Price Outstanding at December 31, 2020 126,173 ​ $ 1.32 Granted ​ — ​ ​ — Exercised ​ — ​ ​ — Outstanding at September 30, 2021 126,173 ​ $ 1.32 ​
Schedule of outstanding warrants	The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants Outstanding ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ Exercise Price ​ Expiration Type Grant Date 2021 2020 per Share Date ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common Warrants ​ 12/19/2019 ​ 61,173 61,173 ​ $ 1.10 ​ 12/19/2024 Common Warrants ​ 3/27/2020 ​ 65,000 65,000 ​ $ 1.5313 ​ 3/27/2025 ​ ​ ​ ​ 126,173 ​ 126,173 ​ ​ ​ ​ ​
Stock Option [Member]
Schedule of fair value of option using Black-Scholes option	The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions to estimate the fair value of stock options issued in the nine months ended September 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 September 30, 2020 Expected volatility 123% - 124 % 104% - 123 % Expected term 6 years 5 6 years ​ Dividend yield 0 % 0 % Risk-free interest rates 0.5 - 1.1 % 0.4 - 1.5 %
Schedule of employee and non-employee stock based compensation expense	Employee and non-employee stock-based compensation expense was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended September 30, ​ Nine months ended September 30, ​ ​ 2021 2020 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ General and administrative ​ $ 654,744 ​ $ 418,147 ​ $ 1,913,005 ​ $ 1,287,474 ​ Research and development ​ 65,537 ​ 68,630 ​ 272,537 ​ 191,460 ​ Total ​ $ 720,281 ​ $ 486,777 ​ $ 2,185,542 ​ $ 1,478,934 ​
Schedule of employee and non-employee stock option	The following is a schedule summarizing employee and non-employee stock option activity for the nine months ended September 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ Weighted Average ​ Aggregate ​ Options Exercise Price Intrinsic Value Outstanding at December 31, 2020 2,361,873 ​ $ 1.89 $ 4,236,737 Granted 1,636,324 ​ 3.95 ​ Exercised (5,883) ​ 1.39 $ 22,761 Expired/Cancelled (149,941) ​ 3.89 ​ Outstanding at September 30, 2021 3,842,373 ​ $ 2.69 ​ $ 5,737,004 Exercisable at September 30, 2021 1,454,788 ​ $ 1.92 ​ $ 3,161,020

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2021
COMMITMENTS AND CONTINGENCIES
Schedule of Future Minimum Rental Payments	​ ​ ​ ​ ​ Years ended Operating Leases 2021 (3 month) ​ $ 32,120 2022 ​ ​ 74,946

ORGANIZATION AND SUMMARY OF S_4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment, Gross	$ 2,397,042	$ 1,569,427
Less accumulated depreciation	(883,467)	(718,580)
Property and equipment, net	1,513,575	850,847
Furniture and fixtures
Property, Plant and Equipment, Gross	55,440	48,676
Laboratory equipment
Property, Plant and Equipment, Gross	2,294,559	1,473,708
Leasehold improvements
Property, Plant and Equipment, Gross	$ 47,043	$ 47,043

ORGANIZATION AND SUMMARY OF S_5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Apr. 29, 2020
Accounting Policies [Line Items]
Cash and cash equivalents	$ 40,839,158		$ 40,839,158		$ 32,665,874
Common Stock, par value (in dollars per share)	$ 0.001		$ 0.001		$ 0.001
Receivables under "ERC"	$ 175,969		$ 175,969
Depreciation			164,887	$ 98,567
Amortization of intangible assets			2,165	3,247
Goodwill and intangible asset impairment			0	0
Research and development	2,513,915	$ 2,629,267	9,307,512	5,711,896
Comprehensive loss	3,931,807	$ 3,910,124	13,831,996	$ 9,478,339
Other income
Accounting Policies [Line Items]
Revenue recognized under "ERC"	$ 367,168		$ 367,168
Paycheck Protection Program Loan
Accounting Policies [Line Items]
Loan amount						$ 318,160
Warrant
Accounting Policies [Line Items]
Antidilutive securities			3,968,546	2,494,068
Minimum
Accounting Policies [Line Items]
Estimated useful lives (in years)			5 years
Minimum | Intellectual Property
Accounting Policies [Line Items]
Intangible assets, useful lives (in years)			5 years
Maximum
Accounting Policies [Line Items]
Estimated useful lives (in years)			7 years
Maximum | Intellectual Property
Accounting Policies [Line Items]
Intangible assets, useful lives (in years)			15 years

NOTE PAYABLE (Details)

NOTE PAYABLE (Details) - Paycheck Protection Program Loan	Apr. 29, 2020USD ($)
Debt Instrument [Line Items]
Amount of loan applied	$ 318,160
Debt term	2 years
Bears interest rate, percentage	1.00%

STOCKHOLDER'S EQUITY (Details)

STOCKHOLDER'S EQUITY (Details) - USD ($)	Jun. 21, 2021	May 04, 2020	Mar. 25, 2020	Dec. 31, 2019	Sep. 30, 2021	May 04, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 21, 2021	Sep. 30, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Commission rate on sale price per share										3.00%
Gross proceeds from sale of common stock							$ 20,175,991	$ 25,908,269
Number of warrants issued					126,173		126,173			126,173	126,173
Beneficial ownership limitation			4.99%
Warrants Outstanding					126,173		126,173			126,173	126,173
Common stock, shares issued					24,149,155		24,149,155			24,149,155	20,577,123
Common stock, shares outstanding					24,149,155		24,149,155			24,149,155	20,577,123
Placement Agent Warrants
Class of Stock [Line Items]
Number of warrants issued			200,000		65,000		65,000			65,000
Exercise price of warrant			$ 1.5313
Effective warrant terms			6 months
Warrants Outstanding			200,000		65,000		65,000			65,000
Exercising Holder [Member]
Class of Stock [Line Items]
Number of shares issued to the exercising holders			724,500
Number of shares being held in abeyance			3,275,500
New Warrants [Member]
Class of Stock [Line Items]
Exercise price of warrant			$ 1.27
Effective warrant terms			5 years 6 months
August 2019 ATM Program
Class of Stock [Line Items]
Number of common stock shares issued						360,316
Average price (in per share)		$ 3.07				$ 3.07
Gross proceeds from sale of common stock						$ 1,100,000
Issuance costs						$ 100,000
December 2019 Financing
Class of Stock [Line Items]
Number of common stock shares issued				531,173
December 2019 Financing | Common Warrants
Class of Stock [Line Items]
Exercise price of warrant				$ 1.226
December 2019 Financing | Pre-funded warrants
Class of Stock [Line Items]
Exercise price of warrant				$ 1.225
Gross proceeds from offering common stock and warrants				$ 5,100,000
December 2019 Financing | Placement Agent Warrants
Class of Stock [Line Items]
Issuance costs				$ 700,000
Number of warrants issued				203,915	61,173		61,173			61,173
Exercise price of warrant				$ 1.5325
Proceeds from issuance of warrants				$ 4,400,000
Warrants Outstanding				203,915	61,173		61,173			61,173
December 2019 Financing | Exercising Holder [Member]
Class of Stock [Line Items]
Issuance costs			$ 400,000
Proceeds from issuance of warrants			$ 4,900,000
May 2020 ATM Program
Class of Stock [Line Items]
Number of common stock shares issued									6,027,852
Gross proceeds from sale of common stock									$ 37,100,000
Issuance costs									$ 1,200,000
Maximum aggregate offering price		$ 40,000,000
Average price	$ 6.15								$ 6.15
June 2021 ATM Program
Class of Stock [Line Items]
Number of common stock shares issued					1,267,475
Gross proceeds from sale of common stock					$ 7,500,000
Issuance costs					$ 300,000
Maximum aggregate offering price	$ 75,000,000
Average price					$ 5.89		$ 5.89			$ 5.89
Maximum | December 2019 Financing | Common Warrants
Class of Stock [Line Items]
Number of warrants issued				4,139,477
Warrants Outstanding				4,139,477
Maximum | December 2019 Financing | Pre-funded warrants
Class of Stock [Line Items]
Number of warrants issued				3,608,304
Warrants Outstanding				3,608,304
Exercise Agreement
Class of Stock [Line Items]
Exercise price of warrant			$ 1.10
Exercise Agreement | Exercising Holder [Member]
Class of Stock [Line Items]
Exercise price of warrant			$ 1.225
Warrant issued exercised			4,000,000
Exercise Agreement | New Warrants [Member]
Class of Stock [Line Items]
Exercise price of warrant			$ 0.125
Warrant issued exercised			4,000,000

STOCK AWARDS, WARRANTS AND OP_3

STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details)	Sep. 30, 2021$ / sharesshares
STOCK AWARDS, WARRANTS AND OPTIONS
Warrants Outstanding at Beginning | shares	126,173
Warrants Outstanding at Ending | shares	126,173
Weighted Average Exercise Price Outstanding at Beginning | $ / shares	$ 1.32
Weighted Average Exercise Price Outstanding at Ending | $ / shares	$ 1.32

STOCK AWARDS, WARRANTS AND OP_4

STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Warrants Outstanding	126,173	126,173
Common Warrants with Expiration on December 2024 One
Class of Warrant or Right [Line Items]
Grant Date	Dec. 19, 2019
Warrants Outstanding	61,173	61,173
Exercise Price per Share	$ 1.10
Expiration Date	Dec. 19, 2024
Common Stock Warrants With Expiration On December 2025 Two
Class of Warrant or Right [Line Items]
Grant Date	Mar. 27, 2020
Warrants Outstanding	65,000	65,000
Exercise Price per Share	$ 1.5313
Expiration Date	Mar. 27, 2025

STOCK AWARDS, WARRANTS AND OP_5

STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, Minimum	123.00%	104.00%
Expected volatility, Maximum	124.00%	123.00%
Expected term	6 years
Dividend yield	0.00%	0.00%
Risk-free interest rates, Minimum	0.50%	0.40%
Risk-free interest rates, Maximum	1.10%	1.50%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		6 years

STOCK AWARDS, WARRANTS AND OP_6

STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation cost	$ 720,281	$ 486,777	$ 2,185,542	$ 1,478,934
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation cost	654,744	418,147	1,913,005	1,287,474
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation cost	$ 65,537	$ 68,630	$ 272,537	$ 191,460

STOCK AWARDS, WARRANTS AND OP_7

STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details) - Stock Option	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)
Number of Options
Outstanding at Beginning of the period | shares	2,361,873
Granted | shares	1,636,324
Exercised | shares	(5,883)
Expired/Cancelled | shares	(149,941)
Outstanding at End of the period | shares	3,842,373
Exercisable | shares	1,454,788
Weighted Average Exercise Price
Outstanding at Beginning of the period | $ / shares	$ 1.89
Granted | $ / shares	3.95
Exercised | $ / shares	1.39
Expired/Cancelled | $ / shares	3.89
Outstanding at Ending of the period | $ / shares	2.69
Exercisable | $ / shares	$ 1.92
Aggregate Intrinsic Value
Exercised | $	$ 22,761
Outstanding | $	5,737,004	$ 4,236,737
Exercisable | $	$ 3,161,020

STOCK AWARDS, WARRANTS AND OP_8

STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details) - USD ($)

Jun. 11, 2021

Jun. 05, 2020

Jan. 01, 2020

Jan. 01, 2019

Jun. 02, 2016

Jan. 31, 2021

Sep. 30, 2021

Sep. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2017

Nov. 30, 2013

Nov. 20, 2013

Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]

Number of options available for issuance

3,836,588

3,836,588

Estimated weighted fair value of option granted (in per share)

$ 4.03

$ 5.23

$ 3.40

$ 3.91

Total unrecognized fair value compensation cost

$ 8,500,000

$ 8,500,000

Weighted average period

1 year 6 months

Stock Option Plan 2012

Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]

Number of shares added

104,547

62,775

Non-Employee Director Plan 2012

Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]

Shares authorized in plans after merger

269,731

Stock Option | Stock Option Plan 2012

Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]

Shares authorized in plans after merger

414,971

414,971

Percentage of outstanding shares

2.00%

2.00%

Stock Option | Stock Option Plan 2020

Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]

Percentage of outstanding shares

4.00%

Number of shares added

823,084

Maximum number of common stock reserved under the Plan

2,500,000

Stock Option | Stock Option Plan 2021

Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]

Percentage of outstanding shares

5.00%

Number of shares added

0

Maximum number of common stock reserved under the Plan

3,500,000

Incentive Stock Option | Stock Option Plan 2012

Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]

Minimum limit of fair market value to be treated as non-statutory stock

$ 100,000

Minimum

Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]

Vesting period

1 year

Maximum

Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]

Vesting period

4 years

Terms of stock option plans

10 years

CONCENTRATIONS (Details)

CONCENTRATIONS (Details)	Sep. 30, 2021USD ($)item
CONCENTRATIONS
Cash, uninsured deposits	$ 40,600,000
Financial Institution One
CONCENTRATIONS
Number of financial institutions | item	2
Cash, FDIC insured amount	$ 250,000

GOVERNMENT GRANT AWARDS (Detail

GOVERNMENT GRANT AWARDS (Details)	Jun. 16, 2016USD ($)item	Sep. 30, 2016USD ($)	Jun. 16, 2016USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2021USD ($)
Revenue from Grant				$ 0
California Institute for Regenerative Medicine
Grant award liability	$ 3,400,000		$ 3,400,000	$ 3,400,000	$ 3,400,000
Minimum expected contribution			$ 2,300,000
Term of award				10 years
Number of times, maximum royalty to be paid on total amount of award | item	9
Debt term				5 years
California Institute for Regenerative Medicine | LIBOR
Interest rate				1.00%	1.00%
U.S. Department of Defense Grant Award
Approved for grant award		$ 2,400,000
Cost incurred under award					$ 2,300,000
Disbursement period		4 years

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details)	Sep. 30, 2021USD ($)
COMMITMENTS AND CONTINGENCIES
2021 (3 month)	$ 32,120
2022	$ 74,946

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - Additional Information (Details)	Jul. 16, 2021USD ($)ft²	Jul. 01, 2013	Nov. 30, 2021USD ($)	Jul. 31, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Oct. 01, 2021USD ($)	Jun. 01, 2014
COMMITMENTS AND CONTINGENCIES
Lease term		2 years
Lease, option to extend		true
Lease renewal term		12 months
Reduction in monthly lease payment			$ 5,548
Future minimum rental payments to related parties					$ 107,066			$ 107,066
Number of months of base salary								6 months
Restructuring reserve					0			$ 0
Operating Lease Right Of Use Asset, lease not Yet Commenced										$ 2,700,000
Operating Lease Liability, Lease Not Yet Commenced										$ 2,700,000
Property Located at 10865 Road to Cure in Diego | CALIFORNIA
COMMITMENTS AND CONTINGENCIES
Lease renewal term	5 years
Ground leases | ft²	9,396
Annual lease rent	$ 600,000
Operating lease percentage	3.00%
Fifth Lease Amendment
COMMITMENTS AND CONTINGENCIES
Written Notice Period								90 days
Monthly lease payment					13,073			$ 13,073
Facilities Lease
COMMITMENTS AND CONTINGENCIES
Lease term											3 years
Lease, option to extend				true
Lease renewal term				12 months
Monthly lease payment				$ 15,805
Leases Monthly Payments for Remainder				$ 10,707
Unrelated Party
COMMITMENTS AND CONTINGENCIES
Operating lease expense					39,219	$ 48,687		117,657	$ 146,061
Related party
COMMITMENTS AND CONTINGENCIES
Operating lease expense					$ 37,218	$ 47,415	$ 47,415	$ 132,048	$ 142,245

LICENSE AGREEMENTS (Details)

LICENSE AGREEMENTS (Details)	Apr. 28, 2021USD ($)	Sep. 30, 2021EUR (€)	Sep. 30, 2021USD ($)	May 31, 2015USD ($)
Accounts Payable and Accrued Liabilities
LICENSE AGREEMENTS
Milestone Payments To Be Made Upon Successful Completion Of Certain Phases			$ 250,000
Rome License Agreement
LICENSE AGREEMENTS
Written Notice Period		90 days
JHU License Agreement
LICENSE AGREEMENTS
Written Notice Period		60 days
Threshold period to cure breach		30 days
CSMC License Agreement
LICENSE AGREEMENTS
Written Notice Period		90 days
Exosomes License Agreement
LICENSE AGREEMENTS
Written Notice Period	90 days	90 days
Upfront Payment	$ 10,000
Minimum | Rome License Agreement
LICENSE AGREEMENTS
Minimum annual royalty payments | €		€ 20,000
Maximum | JHU License Agreement
LICENSE AGREEMENTS
Potential Milestone Payments			1,850,000
Completion of Phase One | Minimum
LICENSE AGREEMENTS
Range of Milestone Payments, Payable Upon Successful Completion of Certain Phases			100,000
Obtention of FDA Approval | Maximum
LICENSE AGREEMENTS
Range of Milestone Payments, Payable Upon Successful Completion of Certain Phases			$ 1,000,000
Completion Of Phase Two Due | JHU License Agreement
LICENSE AGREEMENTS
Milestone Payments To Be Made Upon Successful Completion Of Certain Phases				$ 250,000
Patent rights | JHU License Agreement
LICENSE AGREEMENTS
Agreement effective period		20 years
Patent rights | Exosomes License Agreement
LICENSE AGREEMENTS
Agreement effective period	20 years
Particular Patent or Application or Any Particular Licensed Product | Exosomes License Agreement
LICENSE AGREEMENTS
Written Notice Period	60 days
Non Payment of Royalties | CSMC License Agreement
LICENSE AGREEMENTS
Agreement termination period		30 days
Non Payment of Royalties | Exosomes License Agreement
LICENSE AGREEMENTS
Threshold period to cure breach		30 days
CSMC Agreement Compliance | CSMC License Agreement
LICENSE AGREEMENTS
Agreement termination period		90 days
CSMC Agreement Compliance | Exosomes License Agreement
LICENSE AGREEMENTS
Threshold period to cure breach		90 days
Material Breach Has Not Been Cured | CSMC License Agreement
LICENSE AGREEMENTS
Agreement termination period		90 days
Material Breach Has Not Been Cured | Exosomes License Agreement
LICENSE AGREEMENTS
Threshold period to cure breach		90 days
Fails To Cure Breach after Notice From CSMC | CSMC License Agreement
LICENSE AGREEMENTS
Agreement termination period		90 days
Fails To Cure Breach after Notice From CSMC | Exosomes License Agreement
LICENSE AGREEMENTS
Threshold period to cure breach	60 days	90 days

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	Apr. 01, 2013USD ($)	Sep. 30, 2021USD ($)item	Sep. 30, 2020USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2020USD ($)
RELATED PARTY TRANSACTIONS
Accounts Payable and Accrued Expenses Related Party Current		$ 497,080			$ 8,972
Compensation Received In Connection to Services to be Provided		1,700,000
Related Party Transaction, Other Revenues from Transactions with Related Party		245,000	$ 67,000
Prepaid Expenses and Other Current Assets
RELATED PARTY TRANSACTIONS
Due from Related Parties		0			$ 56,000
Board of Directors Chairman | Sublease Agreement with Frank Litvack
RELATED PARTY TRANSACTIONS
Monthly Sub-lease Income	$ 2,500	0	20,000
Board of Directors Chairman | Consulting Agreement with Frank Litvack
RELATED PARTY TRANSACTIONS
Monthly Consulting Fees to Related Party				$ 10,000
Notice period for termination of agreement				30 days
CSMC
RELATED PARTY TRANSACTIONS
Payment for reimbursement for research and development, license and patent fees and facilities rent expenses incurred by related party		$ 292,400	$ 235,000
Number of clinical trial sponsored | item		2